Journal of Legal Research

Journal of Legal Research

The Duty of Adverse Drug Reaction Alerting from the Perspective of Laws, Current Practices, and Guidelines Related to a Comparative Rights Approach

Document Type : Original Article

Authors
1 PhD in Jurisprudence and Private Law, Faculty of Law and Political Sciences, Kharazmi University, Tehran, Iran.
2 Assistant Professor, Department of Law, Faculty of Law and Political Science, Chalous Branch, Islamic Azad University, Chalous, Iran.
Abstract
From the point of view of production, the current era can be considered as the era of complex products, because we have passed from the era of traditional products to the industrial one and we are witnessing the strong role of industry in the current life of people from life to death. One of the examples of the expansion of industry can be It was clearly observed in the production and supply of pharmaceutical products. Products that are directly related to human health and life play a role in this sensitive valley. The lack of access for all to different biomes in order to obtain traditional medicines is definitely a matter of praise, especially if the producer goes through all the production steps well and without any defects, which will be highly appreciated. If the procedure is carried out properly, it still brings unwanted side effects, which of course, the extent of these side effects also has severity and weakness, and naturally its destructive effects are also different. In the upcoming article, Pira's Warning Duty we will pay attention to the unwanted side effects of medicine and in order to identify the person responsible for the warning, we will stick to the descriptive-normative method. The doctor's consensus has pointed out that we will explain and examine this issue in detail in the next article.
Keywords

Milad, Mashayekh, Shahbazinia, Morteza, Khoeini, Ghafoor. "Production liability with an emphasis on the production of transgenic products", Majlis and Rahbord 92(2018): 29-56. (in Persian
Ghasemzadeh, Sayed Morteza. "Legal analysis of development   risk", Sahami Enteshar Pub, 2015.(in Persian)
Buckner v. Allergan Pharmaceuticals, Inc., 400 So.2d 820,821 (Fla. App. 1981).(in English)
Caroline Richmond, "Obituary — Bill Inman — Medical researcher who revolutionised drug safety rules after the thalidomide crisis" The Guardian (2005): 4 November.(in English)
EC Product Liability Directive (1985).(in English)
 Edwards, Aronson, Adverse drug reactions: definitions, diagnosis, and management, For personal use only, The Lancet Journal, Vol 356, 2000.(in English)
FDA Food Safety Modernization Act (2011).(in English)
Food and Drug Administration Amendments Act (2007).(in English)
Food and Drug Administration Modernization Act (1997). (in English)
Food and Drug Administration Safety and Innovation Act (2012). (in English)
James Beck and Anthony Vale, Drug and Medical Device Product Liability Deskbook. 1 ed. Law journal press, 2004. (in English)
James Kim and Anthony scialli, "Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease",toxicology jornal, 122(2011): 1-6. (in English)
Laurence D, Carpenter J. A dictionary of pharmacology and allied topics, 2nd edn. Amsterdam: Elsevier, 1998. (in English)
Medicines, Poisons and Therapeutic  Goods Act (2008). (in English)
Nebeker JR, Barach P  and  Samore MH, " Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting," . Annals of Internal Medicine 140(2004): 795-801. (in English)
Reporting adverse events to medicines and vaccines(2014). (in English)
The Medicines Act (1968). (in English)
Therapeutic Goods Act (1989). (in English)
World Health Organization, " Pharmacovigilance : ensuring the safe use of medicines," World Health Organization (2004): 1. (in English)
 
http://www.pharmtech.com/about-pharmtech
https://www.ncbi.nlm.nih.gov/pubmed/15148066
http://www.fda.gov.ir/item/2174
  https://www.courtlistener.com/opinion/1281579/belle-bonfils-m-bl-ctr-v-dist-court/
  http://fda.gov.ir/item/1780
  http://www.fda.gov.ir/item/250
 http://www.fda.gov.ir/item/2174
  http://fdo.behdasht.gov.ir/uploads/114_1364_25_zard.pdf
  http://www.fda.gov.ir/item/1106
http://webarchive.nationalarchives.gov.uk/20141206000813/
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32
  https://www.medicalnewstoday.com/articles/196135
  https://www.napolilaw.com/article/medication-caused-side-effects-lead-to-lawsuit/  https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/elmiron_cpm.pdf
  https://www.napolilaw.com/article/prescription-drug-elmiron-may-cause-vision-loss/
  https://www.napolilaw.com/article/prescription-drug-elmiron-may-cause-vision-loss/
  Asia-Pacific Journal of Ophthalmology.
  https://www.drugwatch.com/elmiron/lawsuits/
  https://www.sokolovelaw.com/dangerous-drugs/elmiron/
  https://www.njd.uscourts.gov/elmiron-pentosan-polysulfate-sodium-products-liability-litigation
  https://www.france24.com/en/live-news/20220105-class-action-against-sanofi-wins-french-court-backing
  Apesac) Association d'Aide aux Parents d'Enfants Souffrant du Syndrome de l'Anti-Convulsivant.(
  https://www.fiercepharma.com/pharma/sanofi-ordered-french-court-compensate-epilepsy-drug-side-effects-report
  https://www.novethic.fr/actualite/gouvernance-dentreprise/entreprises-controversees/isr-rse/depakine-le-tribunal-valide-le-principe-d-une-action-de-groupe-contre-sanofi-150466.html
  https://www.legifrance.gouv.fr/loda/id/JORFTEXT000031912641
  https://www.france-assos-sante.org/wp-content/uploads/2019/01/Action-de-groupe-en-sante.pdf
  https://www.editions-legislatives.fr/actualite/depakine-une-decision-inedite/
  https://www.ncbi.nlm.nih.gov/books/NBK430827/
  https://www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-civil-and-political-rights